Get the Stockscreener App
3.74
3.31%
0.12
After Hours:
3.74
Armata Pharmaceuticals Inc stock is traded at $3.74, with a volume of 100.79K.
It is up +3.31% in the last 24 hours and down -32.73% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$3.62
Open:
$3.6
24h Volume:
100.79K
Relative Volume:
0.42
Market Cap:
$139.06M
Revenue:
$5.20M
Net Income/Loss:
$-282.61M
P/E Ratio:
-0.4817
EPS:
-7.764
Net Cash Flow:
$-24.47M
1W Performance:
-10.53%
1M Performance:
-32.73%
6M Performance:
-56.56%
1Y Performance:
+25.50%
1-Day Range:
$3.5601
$3.8065
1-Week Range:
$3.525
$4.56
52-Week Range:
$2.94
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
3.74 | 139.06M | 5.20M | -282.61M | -24.47M | -7.764 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARMP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program - Benzinga
Form 8K Armata Pharmaceuticals Inc For: 23 September By Investing.com - Investing.com Australia
HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target - TradingView
Armata Pharmaceuticals Gets $3.7 Million in Non-Dilutive US Funding - Minichart
Form 8K Armata Pharmaceuticals Inc For: 23 September - Investing.com India
Armata secures new U.S. funding for AP-SA02 Phase 3 - TipRanks
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development - prnewswire.com
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Armata Pharmaceuticals (ARMP) Secures $3.7M in Non-Dilutive Funding to Advance Phase 3 Trials - GuruFocus
H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data - Investing.com
Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history - Yahoo Finance Australia
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates - prnewswire.com
Armata Pharmaceuticals Inc. (ARMP) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation - Yahoo Finance
ARMP Stock Draws Attention As New Phage Data Backs Late-Stage Program - timothysykes.com
Armata Pharmaceuticals stock rises on FDA breakthrough designation By Investing.com - Investing.com Canada
ARMP Stock Pops As Peer-Reviewed Phage Data Backs Late-Stage Program - StocksToTrade
ARMP Stock Draws Bullish Focus After New Phage Breakthrough - timothysykes.com
Form 8K Armata Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com Canada
Armata wins FDA Breakthrough Therapy for AP-SA02 - TipRanks
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 - PR Newswire
Armata Pharmaceuticals Inc (ARMP) Stock Price, Quote, News & History - Benzinga
Deborah Birx is scheduled to present for Armata on Sept. 16 - Stock Titan
Armata Pharmaceuticals Stock Price Forecast. Should You Buy ARMP? - StockInvest.us
Armata Pharmaceuticals (ARMP) Advances Phage Therapy Research Am - GuruFocus
Armata Pharmaceuticals publishes phage research findings By Investing.com - Investing.com Australia
Armata Pharmaceuticals publishes phage research findings - Investing.com
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials - PR Newswire
Armata Pharmaceuticals Inc. (ARMP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Armata Pharmaceuticals Inc. (ARMP) Peer Comparison – Compare with Others - Value Research
JonesTrading Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Armata (ARMP) Results Check: EPS Falls Short of Its Estimate in the Latest Session; Price Reaction - careplusvn.com
Armata (ARMP) Today: Finishes 12.82% Lower at $4.42; Chart View: Price Remains Between $4.20 Support and $4.64 Resistance in the Available RecordLow Volatility Picks - vinanet.vn
Armata (ARMP) Earnings Report: EPS Falls Short of Its Estimate on the Day; Investor Response: The Market Price Advances 11.18%Earnings Preview - vinanet.vn
Madison Asset Management LLC Buys New Position in Armata Pharmaceuticals, Inc. $ARMP - MarketBeat
Armata (ARMP) Earnings Review: The EPS Result Is Below Expectation under the Current Snapshot; Post-Report Move: Shares Rise 1.79%Geographic Revenue Trends - careplusvn.com
ARMP Q1 2026 Earnings: Severe EPS Miss Deepens as Clinical-Stage Costs Pressure Results - vinanet.vn
HC Wainwright Forecasts Armata Pharmaceuticals Q3 Earnings - MarketBeat
Armata Pharmaceuticals, Inc. Revenue Breakdown – AMEX:ARMP - TradingView
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Armata Pharma earnings beat by $0.17, revenue topped estimates - Investing.com
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Is Armata Pharmaceuticals Inc (ARMP) Facing Challenges After Q2 - GuruFocus
Armata Pharmaceuticals, Inc. 2026: Revenue $2.51M, Net income $74.14M, EPS ($0.27) — 10-Q Summary - TradingView
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - PR Newswire
10-Q: Armata Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
ARMP Q1 2026 Earnings: Deep EPS Miss and No Revenue Spotlight Clinical-Stage Cash BurnEarnings Call Highlights - careplusvn.com
[ARMP] Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-than-Expected Net LossQuarterly Financial Update - vinanet.vn
Armata Pharmaceuticals (ARMP) Dips 2% as Shares Approach Key Support at $4.37Breakout Confirmation - vinanet.vn
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):